By Julie Steenhuysen CHICAGO, June 9 (Reuters) - Treatments based on the same mRNA technology that delivered COVID-19 ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

Researchers are particularly encouraged by new data involving a personalized mRNA therapy developed by Moderna and Merck.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine ...

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance ...

A more effective vaccine technology may be on the horizon. In a new study in mice, researchers from the University of Copenhagen demonstrate that a simple addition to mRNA vaccines can significantly ...

Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — So-called mRNA vaccines ...

A new treatment platform developed by researchers at the University of Texas MD Anderson Cancer Center was able to deliver ...